• 제목/요약/키워드: 장기이식

검색결과 404건 처리시간 0.023초

장기이식에 대한 고찰

  • 김수태
    • 과학과기술
    • /
    • 제8권6호통권73호
    • /
    • pp.56-57
    • /
    • 1975

  • 이 기사는 서울국제싸이엔스클럽 제 75차 월례오찬회에서 특강된 내용을 전문수록한 것이다. -편집부-

  • PDF

신장이식 분야의 세포 면역치료 (Cell Therapy in Kidney Transplantation)

  • 전희중;양재석
    • 대한이식학회지
    • /
    • 제28권3호
    • /
    • pp.121-134
    • /
    • 2014

  • Current immunosuppressants have nonspecific immuosuppressive effects, and are not helpful for tolerance induction. Consequently, transplant patients cannot discontinue using them, and their nonspecific immunosuppressive effects result in many side effects, including infection and malignancy. However, most of cellular immunotherapy can have donor antigen-specific immunsuppressive effects. Therefore, cell therapy could be an alternative or adjunctive to nonspecific immunosuppressants. Polyclonal or antigen-specific Foxp3+ regulatory T cells have been actively tried for prevention of acute rejection, treatment of chronic rejection, or tolerance induction in clinical trials. Regulatory macrophages are also under clinical trials for kidney transplant patients. IL-10-secreting type 1 regulatory T cells and donor- or recipient-derived tolerogenic dendritic cells will also be used for immunoregulation in clinical trials of kidney transplantation. These cells have antigen-specific immunoregulatory effects. Mesenchymal stromal cells (MSCs) have good proliferative capacity and immunosuppressive actions independently of major histocompatibility complex; therefore, even third-party MSCs can be stored and used for many patients. Cell therapy using various immunoregulatory cells is now promising for not only reducing side effects of nonspecific immunosuppressants but also induction of immune tolerance, and is expected to contribute to better outcomes in transplant patients.

  • https://doi.org/10.4285/jkstn.2014.28.3.121 인용